Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Szentes – page 20

399 clinical trials in Szentes, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Szentes at a glance
399
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

399 trials in Szentes

Open in trial search

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Neurodermatitis

Not recruiting

Study of Rocatinlimab in Adults with Prurigo Nodularis Not Adequately Controlled by Topical Treatments

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of Bimekizumab and Risankizumab in Adults with Active Psoriatic Arthritis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Obesity+2

Not recruiting

Study on the Effects of Retatrutide for Patients with Obesity, Overweight, or Knee Osteoarthritis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Rheumatoid arthritis

Not recruiting

Study of LY3871801 for Adults with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:LY3871801
  • Sponsor:Eli Lilly & Co.

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

Hodgkin's disease

Not recruiting

Study Comparing Brentuximab Vedotin with Drug Combination for Treating Advanced Classical Hodgkin Lymphoma in Patients

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:Takeda Development Center Americas Inc.

B-cell lymphoma+1

Not recruiting

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study on OM-85 for Preventing Respiratory Infections in Children with Wheezing Illness (Ages 6 Months to 5 Years)

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Sponsor:OM Pharma SA

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not recruiting

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Szentes

What the registry says about research in the country

01 Rheumatology Research

Ongoing clinical trials focusing on Psoriatic Arthritis (PsA) treatments, evaluating novel therapeutic approaches for patients with active disease conditions.

  • Novel Treatment Evaluation
  • Long-term Safety Studies
  • Biologic Therapy Research

Research includes assessment of innovative medications like deucravacitinib and bimekizumab, specifically designed for patients with varying treatment histories.

02 Immunology Studies

Investigation of targeted therapies for autoimmune conditions, with particular emphasis on comparing treatment efficacy against placebo in controlled clinical settings.

  • Treatment Response Analysis
  • Safety Monitoring
  • Patient Tolerance Assessment

Studies focus on both treatment-naïve patients and those with previous exposure to TNFα inhibitors.

03 Therapeutic Development

Comprehensive research into subcutaneous administration of new therapeutic agents for chronic inflammatory conditions.

  • Extended Duration Studies
  • Treatment Efficacy Evaluation
  • Patient Response Monitoring

Trials aim to establish both immediate and long-term benefits of innovative treatment approaches in inflammatory arthritis.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.